Price Alert

Grifols S.A. (GRFS)

NASDAQ: GRFS · Real-Time Price · USD

9.95

-0.07 (-0.70%)

At close: Oct 03, 2025, 3:59 PM

9.70

-2.51%

After-hours: Oct 03, 2025, 04:08 PM EDT

-0.70% (1D)

Bid	8.7
Market Cap	8.42B
Revenue (ttm)	7.45B
Net Income (ttm)	297.45M
EPS (ttm)	0.52
PE Ratio (ttm)	19.13
Forward PE	9.19
Analyst	Hold
Dividends	n/a

Ask	11.39
Volume	663,834
Avg. Volume (20D)	930,622
Open	10.10
Previous Close	10.02
Day's Range	9.94 - 10.13
52-Week Range	6.19 - 11.14
Beta	1.02
Ex-Dividend Date	n/a

About GRFS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GRFS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GRFS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

4 months ago

+8.87%

Grifols shares are trading higher after the compan... Unlock content with Pro Subscription

10 months ago

Grifols shares are trading lower after the company ended discussions with Brookfield Capital Partners regarding a potential acquisition.

News

3 days ago · seekingalpha.com

Grifols: Significant Upside Likely Materializing

Grifols demonstrates strong recovery, with leverage reduced to 4.2x and dividend reinstated, supporting a renewed investment case. GRFS posted robust Q2 2025 results: 7% revenue growth, 12.5% EBITDA g...

1 week ago · zacks.com

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those ...

1 week ago · zacks.com

Should Value Investors Buy Grifols (GRFS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...